




RealRate

PHARMACEUTICAL 2014

Seelos Therapeutics INC
Rank 156 of 234

SEELOS **St**
THERAPEUTICS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Seelos Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seelos Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Seelos Therapeutics INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 178%, being 64% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	22,264
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,760
Liabilities, Non-Current	91
Other Assets	91
Other Compr. Net Income	0
Other Expenses	1,201
Other Liabilities	487
Other Net Income	429
Other Revenues	2,511
Property and Equipment	955
Research and Development	5,123
Selling, General and Administrative Expense	13,554

Output Variable	Value in 1000 USD
Assets	23,310
Liabilities	12,338
Expenses	19,878
Revenues	2,511
Stockholders Equity	10,972
Net Income	-16,938
Comprehensive Net Income	-16,938
BaseVar	29,233
ECR before LimitedLiability	39%
Economic Capital Ratio	178%